Ube Industries, Inc.

Sankyo Company, Limited

Ube Corporation

Shigeru Ushiyama

Tomio Kimura

Noriaki Iwase

Shigeyuki Kono

Yusuke Shiraishi

Masahiro Kojima

Makoto Okudo

Masaaki Ito

Masaaki Matoyama

Hiroshi Nishida

Hidetoshi Sunamoto

Eiji Okanari

Yasuhiro Aga

Koji Ito

Satoshi Umezaki

Sayaka Ogi

Takashi Matsushita

Kazuhiro Onuma

Hirofumi Matsunaga

Kenji Nishikawa

Keisuke Suzuki

Akira Nakao

Masaaki Miyamoto

Ken-ichi Komori

Tetsuo Kawaguchi

Yasunori Tokunaga

Akishi Ninomiya

Hiroyoshi Kawada

Masaru Shinohara

Haruka Yamada

Akihiro Kawara

Yasuo Noguchi

Masayuki Tanaka

Takeshi Oshima

Isao Kawamoto

Tetsushi Katsube

Rokuro Endo

Keiji Ueda

Keiichi Matsuda

Nobuhiko Shibakawa

Kenji Yoneda

Kazuhiko Tanzawa

Tomoko Kanda

Hayato Nishiyama

Kiyoshi Yamamoto

Shoujiro Miyazaki

Wataru Takasaki

The present invention provides a compound of general formula (I) (wherein X is as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.

Substituted guanidine compounds

The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a Calkyl group or the like; and R, Rand Reach independently represent an optionally substituted linear or branched Calkyl group. 

Substituted dihydropyrrolopyrazole derivative

The present invention provides a compound of general formula (I) (wherein, R, X, p and q are as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.

Substituted guanidine derivatives

A novel &#x3b1;-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided. A compound represented by the general formula (I) wherein A represents, a phenyl ring, a thiophene ring, or an isothiazole ring; Ris the same or different, and represents a halogen atom, or a C-Calkyl group; Rrepresents a hydrogen atom, or a C-Calkyl group; p represents an integer of 0 to 5; V represents CRwherein Rrepresents a hydrogen atom, an amino group, a nitro group, or a C-Calkoxy group, or V represents a nitrogen atom; and X represents a halogen atom, or a salt thereof.

Halogen-substituted heterocyclic compound

Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein Lis an optionally substituted Calkylene group or the like, Lis a single bond or the like, Lis a single bond or the like, R, R, and Rare each independently an optionally substituted Calkyl group or the like, Ris a hydrogen atom or the like, and Ris a hydrogen atom or the like.

Substituted dihydropyrrolopyrazole compound

The invention provides a novel &#x3b1;-halogen-substituted thiophene compound salt that has a potent LPA receptor antagonistic action and is useful as a medicament. The salt is represented by the general formula (I):  

Halogen-substituted heterocyclic compound salt

A novel &#x3b1;-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided.

The present invention provides a substituted biaryl compound of general formula (I): 

Substituted biaryl compound

Compounds of formula (I) and (II):[wherein R is hydrogen, halogen or alkyl; Ris alkyl, amino or substituted amino; Ris optionally substituted phenyl; Ris hydrogen, halogen or optionally substituted alkyl; Ris hydrogen, optionally substituted alkyl, cycloalkyl, aryl, or aralkyl] have valuable analgesic, anti-inflammatory, anti-pyretic and anti-allergic activities and have the ability to inhibit the production of leukotrienes and to inhibit bone resorption. They are relatively free from the side effects which generally result from the administration of compounds having these kinds of activities.

1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses

Sulfonamide derivatives

Compounds of formula (I) and (II): ##STR1## �wherein R is hydrogen, halogen or alkyl; R.sup.1 is alkyl, amino or substituted amino; R.sup.2 is optionally substituted phenyl; R.sup.3 is hydrogen, halogen or optionally substituted alkyl; R.sup.4 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, or aralkyl! have valuable analgesic, anti-inflammatory, anti-pyretic and anti-allergic activities and have the ability to inhibit the production of leukotrienes and to inhibit bone resorption. They are relatively free from the side effects which generally result from the administration of compounds having these kinds of activities.

1,2-diphenylpyrrole derivatives, their preparation and their therapeutic

Compounds of formula (I): ##STR1## (wherein n is 0, 1 or 2 and R.sup.1, R.sup.2, R.sup.4, R.sup.5, R.sup.6, X, Y and Z are a variety of groups and atoms) have the ability to inhibit the synthesis of thromboxane A.sub.2 and hence are useful in the treatment or prophylaxis of thrombotic conditions.

Imidazole derivatives as inhibitors of TXA.sub.2 synthesis

Growing community of inventors

Ube, Japan

Shigeru Ushiyama